How One Just Stock Shaved More Than 400 Points Off the Dow on Tuesday
Key Takeaways
- As the S&P 500 and Nasdaq rose Tuesday, the Dow Jones Industrial Average fell 0.8%, dragged down by slumping UnitedHealth Group stock.
- UnitedHealth, one of the priciest stocks in the blue-chip Dow, tumbled nearly 20% Tuesday after reporting disappointing earnings.
- UnitedHealth stock shaved 422 points off the Dow,
» Read more about: How One Just Stock Shaved More Than 400 Points Off the Dow on Tuesday »
Read MoreStock Market Today, Jan. 27: American Airlines Drops on Q4 Miss and Storm Impact
On Jan. 27, 2026, investors weighed a profit miss, a shutdown, and storm hits against fresh long-term earnings guidance and analyst upgrades.
American Airlines Group
Today’s Change
(-7.00%) $-1.02
Current Price
$13.55
Key Data Points
Market Cap
$9.6B
Day’s Range
$13.36 –
Stock Market Today, Jan. 27: UnitedHealth Group Plunges Almost 20% After Weak Earnings
Investors reassess this healthcare giant in wake of profit collapse and Medicare worries, today, Jan. 27, 2026.
UnitedHealth Group
Today’s Change
(-19.61%) $-68.94
Current Price
$282.70
Key Data Points
Market Cap
$319B
Day’s Range
$280.40 –
Tesla Stock: Three Catalysts Nobody Is Seeing
TSLA has experienced impressive surges, with over 30% increases in less than two months happening 18 times, particularly in 2013 and 2024. There were also occasions where gains surpassed 50% within similar time frames, underscoring Tesla’s capacity for swift price increases. If these trends continue, upcoming catalysts could propel TSLA stock to significant new heights,
» Read more about: Tesla Stock: Three Catalysts Nobody Is Seeing »
Read MoreThe Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
Will This ETF 2x Before Year End?
In recent months, some of the most sophisticated investors on Wall Street have made a bold move by pouring hundreds of millions into BlackRock’s iShares Bitcoin Trust (IBIT).
This isn’t just a passing trade but a conviction bet that Bitcoin’s best days may still be ahead and while still trading under $100,000 per coin,
» Read more about: Will This ETF 2x Before Year End? »
Read MoreThe Spotlight
Why This Beverage Giant Can’t Be Toppled
A famous book on business was titled Barbarians at the Gate, documenting the leveraged buyout of RJR Nabisco. If nothing else, it highlights how just the sniff of an opportunity to make money can drive money seekers to make wild decisions.
Some giant businesses have been on the receiving end of similar threats to their solvency as invaders attempt to take their share.
» Read more about: Why This Beverage Giant Can’t Be Toppled »